Overexpression of Paxillin has been reported in a number of different human cancer types (Sobkowicz et al., 2017; Deakin et al., 2012; Yang et al., 2010; Salgia et al., 1999; Mackinnon et al., 2011). Here, PXN is linked to cancer.